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Abstract: 
Drug-induced liver injury (DILI) is an important cause of death and indication for liver 
transplantation (fatality).  The role of DILI in these fatalities ispoorly characterized particularly 
when fatalities occur > 26 weeks after DILI onset.  We analyzed patients in the U.S. Drug-
Induced Liver Injury Network prospective study having a fatal outcome within 2 years of onset.  
Each case was reviewed by 8 Network investigators and categorized as DILI having a primary, 
contributory or no role in the fatality. We subcategorized primary role cases as acute, chronic, 
acute-on-chronic or acute cholestatic liver failure.  For contributory and no role cases, we 
assigned a primary cause of death. Among 1089 patients, 107 (9.8%) fatalities occurred within 2 
years.  DILI had a primary role in 68 (64%), a contributory role in 15 (14%) and no role in 22 
(21%); 2 had insufficient data. Among primary role cases, 74% had acute, 13% chronic, 7% 
acute-on-chronic and 6% acute cholestatic failure.  For the 15 contributory role cases, common 
causes of death included sepsis, malignancy and severe cutaneous reactions with multi-organ 
failure.  For the 22 no role cases, malignancies accounted for most fatalities.  Higher bilirubin, 
coagulopathy, leukocytosis and thrombocytopenia were independently associated with DILI 
fatalities. nR Hy’s Law had a higher positive predictive value for overall fatality (14% vs. 10%) 
and stronger independent association with DILI fatalities within 26 weeks compared to the 
original version of Hy’s Law (HR: 6.2, CI 3.4 – 11.1 vs. 2.2, CI 1.3-3.7).  DILI leads directly or 
indirectly to fatality in 7.6% of cases; 40% of these have non-acute liver failure courses.  nR 
Hy’s Law better identifies risk for death compared to the original Hy’s Law. 
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INTRODUCTION 
 
Most patients suffering hepatotoxicity due to medications, herbal or dietary supplements (HDS) 
recover from the acute liver injury without long-term sequelae.  However, a proportion does not 
survive the injury or require liver transplantation (referred hereafter as a death, mortality, fatality 
or fatal outcome).  Most large registries of drug-induced liver injury (DILI) report a mortality 
rate of approximately 10% 
1-3
.  However, the contribution of DILI in these fatalities is not always 
clear, particularly when they occur more than 26 weeks after DILI onset.  There are emerging 
data on chronic or persistent DILI that continues beyond 6 or 12 months.
4-7
 DILI may also 
contribute significantly to a fatality without being the primary cause of death.  Such cases should 
be analyzed separately, but counted as part of DILI’s disease burden.  Determining the 
contribution of liver injury to a fatality can be difficult, if patient data are not collected 
prospectively and assessed systematically. Lastly, accurate classification of DILI related 
fatalities allows more accurate analyses of predictors of death, such as Hy’s Law and its 
derivations.  
 
For these reasons, we performed a systematic analysis of all patients who had a fatal outcome 
within 2 years of onset in the Prospective Study of the U.S. Drug Induced-Liver Injury Network 
(DILIN).  In addition, we categorized the DILI as playing a primary, contributory or no role in 
the fatality. Using these categories of fatal outcomes, we assessed clinical variables including 
MELD, Hy’s Law and its modified version using a new R-ratio (nR) proposed recently by 
Robles-Diaz et al.
8
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METHODS 
 
Design: The design of the DILIN Prospective Study has been described in detail in previous 
publications.
9,10
  Briefly, all patients suspected of having idiosyncratic drug- or herbal/dietary 
supplement (HDS)-induced liver injury were eligible if they could be enrolled within 6 months 
of onset of the injury and met specific criteria of laboratory abnormalities.  These included serum 
alanine (ALT) or aspartate aminotransferase (AST) greater than 5 times upper limit of normal 
(ULN) (or pretreatment baseline if abnormal) on 2 consecutive occasions; or alkaline 
phosphatase (Alk P) levels greater than 2 times ULN (or pretreatment baseline if abnormal) on 2 
consecutive occasions; or total bilirubin at least 2.5 mg/dL or an INR greater than 1.5 
accompanied by any elevation in AST, ALT, or Alk P.  Acetaminophen overdose cases and cases 
with certain chronic liver diseases such as autoimmune hepatitis and primary biliary cirrhosis 
were excluded.  Subjects were asked to return 6 months after onset, and if laboratory or clinical 
abnormalities related to the liver injury were still present, to return at 12 and 24 months.  At 
enrollment, relevant medical information was extracted from the medical records and interim 
history, physical examination and appropriate laboratory results were obtained.   
 
Causality Assessment and Severity of Injury: The DILIN Prospective Study used a consensus 
expert opinion method of causality assessment.
9,10
  The DILIN investigator who enrolled the 
patient and two investigators from two other centers were provided with a standardized clinical 
narrative and summary of relevant clinical, laboratory, histologic and imaging results.  The three 
investigators independently assign a causality score representing percent likelihood of 
attribution, in which 1 = definite or > 95% likelihood of DILI, 2 = highly likely or 75-95% 
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likelihood, 3 = probable or 50-74%, 4 = possible or 25-49%, and 5 = unlikely or < 25%.  
Consensus on scoring was reached by e-mails and web based conference calls which include all 
DILIN investigators.  Each case was also assigned a severity score of 1 to 5 (5 = fatal or needing 
transplant) based on bilirubin, INR, hospitalization, need for transplant, or fatality.
2
 
 
Study Cohort: We identified all cases enrolled in DILI between September 2004 to April 2015 
and scored as a 1 (definite DILI), 2 (highly likely) or 3 (probable).   We then selected and 
analyzed all patients who died or underwent liver transplantation during the 2-year period of 
follow-up.  For the purposes of this analysis, we refer to all these cases as fatalities or deaths 
even though some survived beyond transplantation.  
 
Categorization by Role of DILI in Death or LT: Clinical death narratives and summaries of serial 
clinical, laboratory, histologic and imaging results were prepared for each case of death or liver 
transplantation in the DILIN Prospective Cohort study.   A Death Review Subcommittee 
consisting of 8 DILIN hepatologists was established, and each case was assigned randomly to 
two members for independent review.  Each reviewer subjectively categorized the cases for 
whether the DILI episode played a primary, contributory or no role in the death.   We resolved 
discrepancies between reviewers by conference call discussion that included the entire Death 
Review Subcommittee.  The Subcommittee had the prerogative to ask that any case be sent back 
for full causality assessment described above, if on review of the fatal outcome, original 
diagnosis of DILI was called into question.  
 
Page 7 of 32
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
Corresponding author: PH Hayashi HEP-16-2486 Death Review DILIN 
 
8 
 
Pattern of liver failure for primary role cases: Cases where DILI clearly played a primary role in 
the death or transplant, had to be subcategorized into 1 of 4, mutually exclusive clinical patterns 
of fatal liver failure: 
1. Acute liver failure (ALF) deaths were defined as acute liver insult with INR ≥1.5, 
hepatic encephalopathy, no evidence of pre-existing, underlying advanced liver disease 
or cirrhosis and death occurring in less than 26 weeks.
11,12
 
2. Acute-on-chronic liver failure (ACLF) deaths were defined as acute liver insult with 
INR ≥1.5, hepatic encephalopathy, and clinical or histologic evidence of pre-existing 
advanced liver disease or cirrhosis and death occurring in less than 26 weeks.
13
  
3. Acute cholestatic liver failure deaths had acute injury with R-value < 2, no pre-existing 
liver disease, no no hepatic encephalopathy and death occurring in less than 26 weeks 
(i.e. acute cholestatic failure not meeting ALF criteria).   
Chronic liver failure (CLF) deaths were defined as acute liver insult with consequent hepatic 
decompensation (e.g. ascites, jaundice, encephalopathy, coagulopathy) with or without evidence 
of pre-existing liver disease and death occurring due to liver failure more than 26 weeks later. 
Cause of death for contributory and no role cases.  Criteria used to categorize DILI as having a 
contributory role in the death included the following: (1) DILI left the patient in a weakened or 
malnourished state which contributed to death by another disease (e.g. cancer), (2) DILI 
prevented necessary care (e.g. surgery or chemotherapy) of another fatal illness, (3) DILI 
exacerbated or was part of another concurrent fatal illness (e.g. sepsis, multi-organ failure, 
DRESS) and (4) the death was due to a complication from a test or procedure done to evaluate 
the DILI (e.g. bowel perforation from an ERCP).   
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No role cases lacked any of the above criteria and often had recovered or nearly recovered from 
the DILI when they died of another illness.  Both contributory and no role cases were then 
assigned 1 of 18 primary causes of death (Supplementary Table 1). We resolved discrepancies 
between reviewers by conference call discussion that included the entire Death Review 
Subcommittee of 8 members.  
 
Descriptive data, clinical variables and analysis: Data analyzed included routine demographic, 
clinical and laboratory test results as well as time from starting the implicated drug or HDS to 
onset of injury and time from injury onset to death or transplantation. The pattern of injury was 
categorized as hepatocellular, cholestatic, or mixed based upon the R-ratio from laboratory tests 
taken at the time of onset:  R-ratio = (ALT / ULN) ÷ (Alk P / ULN). R-ratios greater than 5 were 
considered hepatocellular, less than 2 cholestatic, and 2-5 mixed.  We also classified cases by 
Hy’s Law and the new-R ratio (nR) Hy’s Law criteria at presentation: 
1. Hy’s Law: bilirubin ≥ 2.5 mg/dL, ALT > 3 times ULN and Alk P < 2 times ULN  
2. nR Hy’s Law: bilirubin ≥ 2.5 mg/dL, and [(ALT/ULN) ÷ (Alk P/ULN)] > 5. (AST is 
substituted for ALT, if the AST yields a greater R-ratio). 
8
    
Using these clinical variables, we described those who survived compared to those who died or 
underwent liver transplantation.  We also compared primary, contributory or no role cases.  We 
determined performance characteristics  for MELD, Hy’s Law and nR Hy’s Law for identifying 
mortality risk due primarily or partially to DILI at 2 years, and DILI related ALF and ACLF on 
univariate and multivariate analyses.  
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Statistical Analysis:  Standard descriptive methods (e.g. mean, standard deviation, median, 
quartiles, percentages) were used to describe the total cohort and subgroups.  Comparisons 
between subgroups were performed using standard parametric and non-parametric tests where 
appropriate.  We used Cox proportional hazard ratios to identify clinical variables independently 
associated with overall DILI related deaths (primary or contributory role) at 2 years.  We also 
determined the performance characteristics for MELD, Hy’s Law and nR Hy’s Law (e.g. positive 
predictive value, hazard ratios, C-statistic) in predicting deaths from DILI related ALF and 
ACLF.    
 
Role of Funding Source and Institutional Board Review (IRB): The DILIN Network is structured 
as a U01 cooperative agreement with funds provided by the National Institute of Diabetes and 
Digestive and Kidney Diseases (NIDDK).  Separate IRB approvals were maintained at each 
DILIN center throughout the period of this study and protocols were approved and all data 
monitored by a separate Data Safety and Monitoring Board appointed by the NIDDK.
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RESULTS 
 
Subjects: As of April 10, 2015, a total of 1509 patients were enrolled in the DILIN Prospective 
Study of which 1332 underwent formal causality assessment and 1089 were judged to have 
definite, highly likely or probable DILI.  Among these, 107 (9.8%) died or underwent liver 
transplantation (all cause mortalities) within 2 years of onset. (Figure 1). The Death Review 
Subcommittee did not send any of the 107 fatalities back for causality reassessment. 
 
Comparison of patients who survived with those who died or underwent liver transplantation is 
shown in Table 1. Patients with a fatal outcome were on average somewhat older than those who 
survived (mean = 53.1 vs 48.5 years) but were similar in other demographic aspects.  Initial 
laboratory results showed higher levels of ALT, AST, bilirubin and INR in those with fatal 
outcome, but the R-ratio and distribution of patterns of injury were similar.  Fatalities had higher 
proportions meeting Hy’s Law and nR Hy’s Law criteria but only the latter reached statistical 
significance. 
 
Categories by Role of DILI in Death or Transplant: DILI was considered to have a primary role 
in the death or need for transplantation in 68 (64%) patients. (Figure 1)  DILI had a contributory 
role in 15 cases (14%), and no role 22 (21%).  The role could not be determined due to 
insufficient follow-up details for 2 patients.   The clinical and laboratory features associated with 
the three categories are shown in Table 2.  Patients in whom DILI was the primary cause of 
death were younger, more likely female, had higher levels of ALT, AST, bilirubin, INR and R-
ratio, and were more likely to have hepatocellular injury than no role cases. Contributory role 
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cases had features more like no role cases, except for female sex, which was similar to primary 
role cases.  A higher proportion of primary role cases met Hy’s Law criteria (40.3%) compared 
to contributory or no role cases, but the difference was statistically significant only when 
compared to no role cases. (Table 2) An even higher proportion of primary role cases met nR 
Hy’s Law (65.6%) and was statistically higher than either contributory or no role cases.  Listing 
and frequency of specific agents are shown in Supplemental Tables 2-5. 
 
Clinical course of liver failure in DILI Primary Role cases: Clinical features of the patients in 
which DILI played a primary role in the fatal outcome are shown in Table 3, sub-categorized by 
their clinical course of liver failure. Of these 68 primary role cases, 50 (74%) had ALF as shown 
by marked elevations in serum ALT and AST levels with relatively mild increases in Alk P and a 
median time to death or transplant of 24 days (range 2 to 123 days). Another 5 (7%) patients had 
acute-on-chronic liver failure with less marked increases in ALT and AST (and AST > ALT).  
Time to death or transplant ranged from 6 to 135 days.  Nine patients (13%) had a DILI related 
chronic liver failure accompanied by lower median values for ALT and AST and higher values 
for Alk P. For 7 of these 9, time from DILI onset to death or transplant ranged from 217 to 410 
days.  The other two had liver injury from methotrexate and amiodarone, both known to cause 
gradual fibrosis accumulation with only modest enzyme elevations. Therefore a precise onset of 
DILI for these agents was indeterminable, but the exposure time for the amiodarone was 847 
days and for methotrexate 2129 days.  Finally, four patients (6%) had a rapidly progressive 
cholestatic course resulting in liver failure and death in 3 and transplantation in 1.  Death or 
transplant occurred 48 to 171 days of onset in these four, who tended to be older (ages 75, 65, 61 
and 48).   Acute and acute-on-chronic liver failure cases had significantly higher proportions 
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meeting Hy’s Law and nR Hy’s Law criteria (40-79%), compared to relatively few patients 
meeting such criteria in the chronic or acute cholestatic groups (0-25%) (Table 3).   
 
Gender, race and ethnicity did not differ significantly among the cases with different patterns of 
liver failure, although those with typical acute liver failure tended to be younger (mean age 48.7 
years) than patients with other patterns. The percentage of liver transplantations was low for 
acute-on-chronic liver failure (1 of 5: 20%) and for acute cholestatic liver failure (1 of 4: 25%) 
and higher for chronic liver failure (5 of 9: 56%) and acute liver failure (34 of 50: 68%).   
 
Causes of death in Contributory Role cases:  Of the 15 patients whose DILI was considered to 
play a contributory role, the primary causes of death were judged to be sepsis in 3, malignancy in 
3, another unrelated liver disease in 3 (nonalcoholic liver disease in 1 and autoimmune hepatitis 
in 2) and severe cutaneous reaction with systemic complications in 3. (Figure 2)  In many 
situations, the role of the liver injury was difficult to assess, the underlying co-morbidities being 
severe and potentially fatal on their own.  In these situations, the episode of DILI was believed to 
hasten the fatal outcomes.   
 
Causes of death in No Role cases: Of the 22 patients where DILI played no role in the outcome, 
malignancies accounted for over half of cases (12; 55%).  The remaining patients died from a 
variety of causes shown in Figure 2.  
 
Specific agents leading to fatality:  Specific agents and HDS products as a whole are shown in 
frequency tables by role of DILI in the fatalities. (Supplemental Tables 2-5). 
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Variables associated with death or liver transplant: We compared patients with DILI related 
death or liver transplantation (primary and contributory role patients, n = 83) to the rest of the 
cohort (survivors, no role cases and unknown role cases = 1006) (Figure 1). Variables associated 
with fatality due primarily or partially to DILI on univariate and multivariate analyses are shown 
in Tables 4.   Higher bilirubin, higher INR, lower platelet count, and lower albumin were 
associated with mortality.     
 
Hy’s Law,nR Hy’s Law and MELD:  Hy’s Law had a lower positive predictive value for deaths 
primarily or partially due to DILI up to 2 years after onset compared to nR Hy’s Law (10% 
versus 14%).  Specificities were about the same at 71% and 69%, respectively.  When limited 
only to deaths primarily due to DILI, the positive predictive values fell to 8% for Hy’s Law and 
12% for nR Hy’s Law.  Specificities did not change.  Because Hy’s Law and especially MELD 
were put forth to predict shorter term mortality, we also analyzed their association with DILI 
fatalities occurring within 26 weeks due to acute liver failure or acute on chronic liver failure.  
On this multivariate analysis, Hy’s Law was significantly associated with early mortality 
primarily due to DILI (HR: 2.2, CI 1.3-3.7).  However, the association with nR Hy’s Law was 
stronger (HR: 6.2, CI 3.4 – 11.1) and with MELD stronger still.  The HR per MELD point was 
1.2 (CI 1.1 – 1.2), and at various MELD cut-offs, the HRs were all over 10. (Supplemental Table 
6)  C-statistic for a MELD cut-off of 19 was 0.83 compared to 0.73 for nR Hy’s Law and 0.60 
for Hy’s Law    For the Hy’s Law Cox regression analyses, ALT, AST and bilirubin were 
excluded as they are part of Hy’s Law and the nR Hy’s Law.    INR, creatinine and bilirubin 
were excluded in the Cox modeling for MELD. 
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DISCUSSION: 
 
It is well known that DILI can lead to death or liver transplant (fatal outcome), but the precise 
role and course of DILI in these cases is poorly defined particularly when fatalities occur more 
than 26 weeks after liver injury.  In the DILIN prospective cohort, 107 of 1089 patients with 
definite, highly likely or probable DILI had a fatal outcome within 2 years of onset.  Thus, the 
all-cause fatality rate was 9.8%. (Figure 1). Fatalities tended to be older, have more 
hepatocellular injury and more underlying chronic liver disease than patients who survived 
(Table 1).   Their DILI causality assessments also tended to be less certain, probably because the 
recovery, or washout, phase was truncated by the death.  The majority of the fatalities were 
related to DILI, being the primary cause of death in 68 patients and a contributing cause in 
another 15.  The remaining 22 patients had fatal outcomes unrelated to DILI. (Figure 1) 
Therefore, the DILI fatality rate (primary or contributory) was 7.6% (83/1089).  This rate 
increased to 9.5% (68/712) if the denominator is limited to those presenting with jaundice 
(bilirubin ≥ 2.5 mg/dL). 
 
Comparing DILI primary, contributory and no role cases revealed important differences. (Table 
2)  Primary and contributory role cases were predominantly women compared to no role cases 
who were predominantly men.  Primary role cases were younger and usually followed a course 
typical of acute liver failure (ALF) (50 of 68, 74%). As expected, the majority (83%) of ALF 
cases presented with a hepatocellular pattern of enzyme elevations (high R-ratios). (Table 3)  
This predominance of ALF is in line with DILI being a leading cause of ALF in the U.S.
14,15
 Our 
cases were similar to those reported by the US ALF Group.  Most were young (<45) and women.  
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Antimicrobials, isoniazid in particular, were the most common agents implicated but herbal and 
dietary supplements were also prominent (Supplemental Tables 2-4).  The majority of patients 
with ALF were listed for liver transplantation (74%), and most of these were transplanted (68%).  
The remaining ALF patients were not listed due to medical or psychosocial contraindications.   
 
DILI fatality by non-ALF injury patterns has not been well described, though a quarter of the 
DILIN deaths due directly to DILI followed such non-ALF courses.  Five (7%) of the 68 primary 
role cases had underlying cirrhosis and were categorized as acute-on-chronic liver failure.  For 
this study, we defined acute-on-chronic liver failure as a case with pre-existing cirrhosis and 
DILI being the primary cause of death or LT within 26 weeks of onset.  Our dataset did not have 
the clinical information to determine more recently developed CLIF (Chronic Liver Failure) 
classifications and scores.
16,17
  Of the 5 acute-on-chronic cases, 3 were listed for transplant but 
only one received a liver.  The other two became too ill and were removed from listing.  The 
listed cases may not have met criteria for priority listing (Status 1a) due to their underlying 
cirrhosis, which could explain the lower rate of transplantation. 
 
Another 9 (13%) of the 68 primary role cases had a fatality due to chronic liver failure.  These 
cases died or needed LT more than 26 weeks after DILI onset.  Agents leading to chronic liver 
failure were varied with 3 of 9 being HDS products and another 3 were antibiotics.  
(Supplemental Table 4) Amiodarone and methotrexate, both known to cause an insidious fibrosis 
accounted for one each.  Chronic liver injury after DILI has been previously described by our 
group and others.
6,7
    While the definition, incidence and significance of chronic DILI is unclear, 
this study clearly documents a small number of fatalities due to prolonged liver injury from 
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DILI.  These 9 cases had lower initial transaminases and R-ratios compared to those with ALF 
and ACLF, but no other distinguishing features could be gleaned from this small number of cases 
(Table 3).  Larger numbers with robust prospective follow-up will be needed to fully understand 
these more insidious DILI deaths. 
 
Four (6%) of the 68 primary role patients had a rapid (< 26 weeks) and progressive cholestatic 
injury. DILI causing such severe cholestatic injury with ductopenia has been described.
18-20
  
These four all died or required transplant within 26 weeks of DILI onset.  They tended to be 
older, three being over 60.  Two had a cholestatic pattern of injury from onset to demise, while 
two presented with a hepatocellular pattern of injury (R ratio just over 5) that quickly 
transitioned to cholestatic.  The R ratios were less than 1 in all four at time of death or transplant. 
One patient underwent LT and the explant histology showed absence of bile ducts.  The 
remaining 3 had medical or psychosocial contraindications to transplantation.  Liver biopsies in 
these three did not show ductopenia but biopsies may have been obtained too early to capture 
vanishing bile duct histology.  Autopsy liver tissuewere not available for these cases. 
 
DILI as a contributing cause of fatality has been poorly defined and rarely reported. Yet, such 
contributory role in deaths may be an important part of DILI disease burden.  In this series, DILI 
contributed to death by worsening of an underlying liver disease (20%) or by contributing to a 
non-liver related death such as DRESS/SJS, sepsis or malignancy (20% each). (Figure 2) In the 
three patients with cancer, DILI significantly limited subsequent therapeutic options.  In one 
case, evaluation of liver injury included an ERCP that was complicated by a fatal duodenal 
perforation.   
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While categorizing DILI as a primary versus contributory cause of death was occasionally 
difficult, assigning it as having no role was often straightforward.  Many of these deaths occurred 
well after DILI had resolved.  The majority of these cases were due to progression of a 
malignancy. (Figure 2).  Certain comorbidities could forebode poor outcome even after apparent 
liver recovery.  Identifying such factors by a comorbidity index (e.g. Charleson, Elixhauser) 
would be useful, but unfortunately the DILIN does not capture the detailed information on 
comorbidities needed to complete such indices. 
 
After we had categorized all fatalities, we identified variables associated with DILI-related 
deaths (primary and contributory role cases). The current analysis differs from our prior studies 
examining DILI fatalities at just 26 weeks.
2,5
  In this study, we included fatalities up to 2 years 
after DILI onset.  Also, categorization of DILI’s role in the fatality was done using a systematic 
approach and by a subcommittee of DILIN investigators, who used a new contributory role 
category and subcategorization of primary role cases by pattern of liver demise.  
 
Variables independently associated with overall DILI related fatality were all plausible.  Higher 
INR, higher bilirubin and lower albumin all reflect more severe liver dysfunction at onset.   
Higher WBC could reflect more immune mediated injury or concurrent infection (i.e. sepsis).  
The association of  mortality with lower platelets is in line with a recent study identifying 
thrombocytopenia with poor outcome for ALF in general.
21
 The lower platelet count may reflect 
multi-organ failure, sepsis or disseminated intervascular coagulation.  Interestingly, pre-existing 
chronic liver disease was not associated with mortality on multivariate analysis, though it was on 
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univariate.  This finding is similar to our two prior studies that found an association between 
chronic liver disease and short term mortality on univariate analysis only. Neither study detected 
an independent association.
2,5
 With the inclusion of deaths up to 2 years later and DILI 
contributory role deaths, we thought this variable might now be independently associated.  The 
persistent lack of association could be due too few patients to detect a smaller increased risk 
(under powered) or the risk may apply only to more advanced liver disease.  Our definition of 
prior chronic liver disease did not specify degree of fibrosis or liver dysfunction.   
 
We show an incremental improvement in Hy’s Law by use of the modified nR form.
8
 For deaths 
due primarily or partially to DILI, Hy’s Law had a 10% PPV precisely in line with Dr. 
Zimmerman’s original suggestion.
22
  However, the nR modification of Hy’s Law yielded a 
higher PPV at 14%.  The difference lay primarily in the ability to identify those who would die 
of DILI related ALF: 79% of ALF fatalities met nR Hy’s Law versus only 52% meeting standard 
Hy’s Law. (Table 3)  The Alk P < 2x ULN criteria explained all the ALF deaths which met nR 
Hy’s Law but not standard Hys’ Law. In Dr. Zimmerman’s text, the limit for alkaline 
phosphatase was < 1-3x ULN, but a cut-off of 2x ULN is typically used.
5,8,22
  The ALF fatalities 
not meeting Hy’s Law had Alk P/ULN ratios ranging from 2.0 to 3.5, low enough to yield an R-
ratio > 5, but too high for standard Hy’s Law.  Thus, the use of nR Hy’s Law over the traditional 
Hy’s Law as a positive predictor of increased risk of death due to DILI may be warranted in 
clinical practice and drug development.    
 
Compared to Hy’s Law or nR Hy’s Law, MELD was a better predictor of acute DILI deaths (< 
26 weeks) by ALF and ACLF. (Supplemental Table 6) The hazard ratio for a MELD greater than 
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19 was 35.6 with a C-statistic of 0.83, compared to a HR of 2.2 and C-statistic of 0.60 for Hy’s 
Law and 6.2 and 0.73 for nR Hy’s Law. MELD probably had a small advantage of often being 
calculated later because INR was not always obtained with the first set of elevated liver enzymes. 
More importantly, Hy’s Law and MELD were put forth for different purposes.  Dr. Zimmerman 
shared his astute observation as a warning to clinicians to be vigilant of a severe outcome when 
hepatocellular DILI meets certain ALT, Alk P and bilirubin criteria.  As such, it was merely a 
positive predictive value set low at 10% to cast a wide net for patients needing close follow-up.  
On the other hand, MELD was based on multivariate modeling to predict mortality risk 
surrounding therapeutic interventions, first TIPS and then transplant, where predictive precision 
is the goal, and not just a low threshold positive predictive value.   
 
In this systematic examination of fatalities prospectively followed in the DILIN, 7.6% of patients 
died primarily or partially from the DILI within two years of onset.  When DILI was the primary 
cause of death, typical acute liver failure (ALF) accounted for most fatalities, but one-quarter had 
non-ALF courses including acute-on-chronic, chronic and progressive cholestatic liver failure.  
When DILI contributes to death, most fatalities were due to sepsis, malignancy, DRESS/SJS or 
worsening pre-existing chronic liver disease.  However, pre-existing liver disease was not 
independently associated with fatality from DILI.  The nR modification of Hy’s Law improved 
the positive predictive value for those at risk of death from acute hepatocellular injury by 
accepting moderately higher alkaline phosphatase elevations into the criteria.  The nR 
modification also has a stronger the association with deaths within 26 weeks directly related to 
DILI, but neither outperformed MELD in predictive value. 
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Table 1: Characteristics of patients dying or requiring liver transplantation within 2 years of 
DILI onset (n = 107) compared to those alive at 2 years without liver transplantation.  
 
Characteristic 
Died/LT within 2 years  
post DILI 
(n = 107) 
Alive at 2 years  
post DILI 
(n = 982) 
p-value 
    
Mean age, yr. (SD) 53.1 (16.4) 48.5 (17.0) 0.01 
Gender, female (%) 57 (53.3%) 577 (58.8%) 0.30 
Mean BMI, kg/m
2
 (SD) 28.7 (6.82) 27.4 (6.81) 0.01 
Race/Ethnicity 
   White 76 (72%) 781 (80%) 
0.10 
   Black 17(16%) 110/ (11%) 
   Asian 7(7%) 30 (3%) 
   Other and Unknown 7/(7%) 62 (6%) 
   Latino 6 (6%) 110 (11%) 0.10 
Alcohol Use 48/104 (46%) 501 (52%) 0.30 
Chronic liver disease 13/62 (21%) 144/866 (17%) 0.50 
Liver biochemistries at DILI onset—Mean (SD) 
   ALT, U/L 1162 (1326) 787 (1064) 0.02 
   AST, U/L 1093 (1199) 634 (993) <0.01 
   Alk P U/L 281 (217) 280 (249) 0.36 
   Bilirubin, mg/dL 10.1 (8.0) 6.3 (6.3) <0.01 
INR  2.2 (1.8) 1.3 (0.7) <0.01 
R-ratio^ 14.9 (19.8) 12.7 (25.16) 0.43 
Pattern of injury (102/925) 
   Hepatocellular 61 (60%) 497 (54%) 
0.11    Mixed 15 (15%) 220 (24%) 
   Cholestatic 26 (26%) 208 (23%) 
Causality Category 
   Definite 16 (15%) 253 (25.8%) 
<0.01    Highly likely 45 (42%) 523 (53.3%) 
   Probable 46 (43%) 206 (21.0%) 
Hy’s Law ∆ 34/101 (33.7%) 269/913 (29.5%) 0.42 
nR  Hy’s Law ° 50/103 (48.5%) 292/936 (31.2%) <0.01 
 
LT = liver transplantation 
SD = standard deviation  
^ R-ratio = (ALT/ULN) ÷ (Alk P/ULN).   
∆ 
bilirubin ≥ 2.5 mg/dL, ALT > 3x ULN and Alk P < 2x ULN at presentation 
° bilirubin ≥ 2.5 mg/dL & R-ratio > 5 at presentation. (AST substituted for ALT, if AST yields greater R-ratio) 8 
 
  
Page 23 of 32
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
Mortality and Transplantation after DILI Dec 17, 2016 DILIN Study 
2 
 Corresponding author: PH Hayashi (paul_hayashi@med.unc.edu) 
 
Table 2: Comparison of patients dying or requiring liver transplantation within 2 years of DILI 
onset (n = 105*) by DILI role in death or need for transplant.  
Characteristic 
DILI Role in Death or Need of LT 
n = 105* 
p-values 
Primary 
n = 68 
Contributory 
n = 15 
No role 
n=22 
Primary vs. 
Contributory 
Primary 
vs. 
No Role 
Mean age, yr. (SD) 50.7 (16.0) 58.9 (16.2) 57.9 (17.2) 0.06 0.08 
Gender, female 42 (62%) 9 (60%) 6 (27%) 0.89 0.01 
Mean BMI, kg/m
2
 (SD) 29.2 (6.7) 31.3 (9.1) 25.6 (4.8) 0.31 0.02 
Race/Ethnicity 
White 46 (69%) 12 (80%) 17 (77%) 
0.95 0.58 
Black 11 (16%) 2 (13%) 3 (14%) 
Asian 6 (9%) 1 (7%) 0 (0%) 
Other 4 (6%) 0 (0%) 2 (9%) 
Latino 5 (7%) 1 (7%) 0 (0.0%) 1.00 0.33 
Alcohol Use 35/66 (53%) 4/14 (29%) 9/22 (41%) 0.10 0.33 
Chronic liver disease 11 (16%) 3 (20%) 6 (27%) 0.13 0.25 
Liver biochemistries at DILI onset 
ALT, U/L 1470 (1483) 587 (694) 579 (740) 0.02 <0.01 
AST, U/L 1422 (1326) 503 (589) 446 (547) 0.01 <0.01 
Alk P U/L 252 (150) 343 (326) 331 (288) 0.34 0.66 
Bilirubin mg/dl 11 (7.5) 9.6 (8.8) 6.6 (7.5) 0.31 <0.01 
INR  2.2 (1.0) 2.4 (2.1) 1.6 (0.9) 0.43 0.17 
R-ratio^ 18.6 (22.4) 6.5 (6.6) 9.2 (15.5) 0.04 0.02 
Pattern of injury 
Hepatocellular 50 (74%) 6 (40%) 8 (36%) 
<0.01 0.01 Mixed 4 (6%) 6 (40%) 5 (23%) 
Cholestatic 14 (21%) 3 (20%) 9 (41%) 
Causality Category 
    Definite 9 (13%) 1 (7%) 5 (23%) 
0.61 0.23     Highly likely 26 (41%) 5 (33%) 11 (50%) 
    Probable 31(46%) 9 (60%) 6 (27%) 
Hy’s Law 
∆
 25/62(40.3%) 5/15 (33.3%) 3/22 (13.6%) 0.62 0.02 
nR  Hy’s Law ° 42/64(65.6%) 5/15 (33.3%) 2/22 (9.1%) 0.02 <0.01 
*DILI role could not be determined in two patients. 
SD = standard deviation  
^ R-ratio = (ALT/ULN) ÷ (Alk P/ULN) 
∆ 
bilirubin ≥ 2.5 mg/dL, ALT > 3x ULN and Alk P < 2x ULN at presentation 
° bilirubin ≥ 2.5 mg/dL & R-ratio > 5 at presentation. (AST substituted for ALT if AST yields greater R-ratio) 
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Table 3: Characteristics and course of liver failure in those patients who died or needed liver 
transplantation due primarily to DILI. Values are means (SD) for continuous variables 
Characteristic 
Primary Role Cases 
n = 68 
 
Acute Liver 
Failure 
n = 50 
Acute on 
Chronic Liver 
Failure 
n = 5 
Chronic 
Liver 
Failure 
n= 9 
Rapid 
Cholestatic 
Liver Failure 
n=4 p-value 
Mean age, yr. (SD) 48.7 (16.9) 60.1 (11.0) 51.5 (11.9) 62.3 (11.2) 0.19 
Gender, female 31 (62%) 3 (60%) 6 (67%) 2 (50%) 0.96 
Mean BMI, kg/m
2
 (SD) 29.2 (7.3) 27.3 (7.1) 28.6 (4.2) 33.0 (2.6) 0.36 
Race/Ethnicity 
White 33 (67%) 2 (40%) 7 (78%) 4 (100%) 
0.66 
Black 8 (16%) 1 (20%) 2 (22%) 0 (0%) 
Asian 5 (10%) 1 (20%) 0 (0%) 0 (0%) 
Other or unknown 4 (6%) 1 (20%) 0 (0%) 0 (0%) 
Latino 4 (8%) 0 (0%) 0 (0%) 1 (25%) 0.49 
Alcohol Use** 28/48 (58%) 2/5 (40%) 4 (44%) 1 (25%) 0.54 
Time (days) from onset 
to Death/LT 35 (28) 59 (50) 236  (120) 132 (91) <0.01 
Liver biochemistries at onset 
ALT, U/L 1864 (1534) 451 (449) 330 (478) 395 (248) <0.01 
AST, U/L 1807 (1348) 699 (717) 279 (347) 375 (217) <0.01 
Alk P U/L 240 (108) 191 (133) 226 (106) 523 (367) 0.26 
Bilirubin, mg/dL 12.5 (7.2) 11.3 (7.4) 7.0 (7.3) 2.9 (2.3) 0.01 
INR  2.7 (2.0) 2.3 (0.7) 1.7 (1.1) 1.1 (0.0) 0.03 
R-ratio^ 24.4 (23.7) 4.5 (3.4) 5.5 (11.6) 3.3 (2.9) <0.01 
Pattern of injury (n)                   (45)                        (5)                     (9)                     (4) 
Hepatocellular 38 (84%) 3 (60%) 2 (22%) 2 (50%) 
<0.01 Mixed 3 (7%) 0 (0%) 1 (11%) 0 (0%) 
Cholestatic 4 (9%) 2 (40%) 6 (67%) 2 (50%) 
Causality Category 
    Definite 9 (18%) 0 (0%) 0 (0%) 0 (0%) 
0.33     Highly likely 19 (38%) 1 (20%) 4 (44%) 3 (75%) 
    Probable 22 (44%) 4 (80%) 5 (56%) 1 (25%) 
Hy’s Law ∆ 23/45(51.1%) 2/5 (40.0%) 0/8 (0.0%) 0/4 (0.0%) <0.01 
nR Hy’s Law ° 37/47(78.7%) 3/5 (60.0%) 1/8 (12.5%) 1/4 (25.0%) <0.01 
^ R-ratio = (ALT/ULN) ÷ (Alk P/ULN) 
∆ 
bilirubin ≥ 2.5 mg/dL, ALT > 3x ULN and Alk P < 2x ULN at presentation 
° bilirubin ≥ 2.5 mg/dL, and R-ratio > 5 at presentation. (AST is substituted for ALT if AST yields greater R-ratio) 
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Table 4: Variables significantly associated with fatalities due primarily (primary role) or partially 
(contributory role) to DILI on univariate and multivariate analysis:  
 
Variable 
Cox Regression 
Univariate  Multivariate  
Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value 
Race     
     Caucasian Referent ---   
     Black 1.5 (0.8, 2.8) 0.16   
     Asian 3.4 (1.6, 7.5) <0.01   
     Other 1.1 (0.4, 3.0) 0.89   
BMI (kg/M
2
) 1.04 (1.0, 1.1) 0.01   
Diabetes 2.3 (1.5, 3.5) <0.01   
Heart failure 3.3 (1.2, 9.0) 0.02   
Chronic Liver disease 1.9 (1.1, 3.3) 0.03   
Neutropenia 3.6 (1.1, 11.4) <0.01   
SJS/DRESS 5.0 (1.2, 20.5) 0.02   
INR at onset +/-14 days 1.5(1.4, 1.6) <0.01 1.6(1.4, 1.7) <0.01 
ALT (per 50 U/L) 1.01 (1.0, 1.01) <0.01   
Total bilirubin (mg/dL) 1.1 (1.0, 1.1) <0.01 1.1(1.0, 1.1) <0.01 
Hemoglobin (g/dL) 0.9 (0.8, 1.0) 0.05   
White blood cells (10
9
/L) 1.1 (1.0, 1.1) <0.01 1.06 (1.02, 1.10) <0.01 
Platelets (10
10
/L) 0.99 (0.99, 0.99) <0.01 0.99( 0.99,0.99) <0.01 
Albumin (g/dL) 0.4 (0.3, 0.5) <0.01 0.4(0.3, 0.6) <0.01 
Corticosteroids given 3.3 (2.2, 5.1) <0.01   
 
 
 
 
Page 26 of 32
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
  
 
 
 
 
165x143mm (300 x 300 DPI)  
 
 
Page 27 of 32
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
